As $2B 'superplant' moves ahead, Samsung Biologics touts plans for fifth facility at South Korean site
Samsung Biologics already has three plants in Songdo, Incheon, South Korea, and another on the way — and it just gained approval to build a fifth.
The company will build a production site for genetic medicines, The Korea Herald reported, after the Incheon Free Economic Zone Authority gave the OK to a purchase of 32,808 square feet in the city. That site will be completed by 2023, if all goes according to plan, and Samsung will spend $259 million on its construction.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.